Hormonal
Tirzepatide use is associated with a significantly increased risk of gastrointestinal adverse events (GIAEs), with nausea and diarrhea being the most frequent, and eructation and impaired gastric emptying showing the highest disproportionality.
If you start tirzepatide, expect gastrointestinal side effects like nausea or diarrhea, especially in the first few months. The risk is higher if you are male, over 65, have Type 2 Diabetes, or take other medications. Working with your doctor to start with a low dose and increase it slowly can help your body adjust and reduce these side effects.
FAERS data showed that nausea (27.7%) and diarrhea (12.8%) were the most frequently reported events, whereas eructation and impaired gastric emptying had the highest disproportionality.
Why this rating
Based on large-scale real-world pharmacovigilance data (FAERS), but subject to reporting bias and lack of controlled dosing/severity data.
Source
Gastrointestinal adverse events associated with tirzepatide: A bibliometric and pharmacovigilance analysis
Peng Shen et al. · PLoS ONE · 2026
DOI 10.1371/journal.pone.0344289
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →